Literature DB >> 1996961

Group B streptococci inactivate complement component C5a by enzymic cleavage at the C-terminus.

J F Bohnsack1, K W Mollison, A M Buko, J C Ashworth, H R Hill.   

Abstract

Incubation of recombinant human C5a (rC5a) with the 7360 strain of group B streptococci (GBS) destroyed the ability of rC5a to stimulate chemotaxis or adherence of purified human polymorphonuclear leucocytes (PMNs). Treatment of 125I-labelled rC5a with GBS 7360 correspondingly decreased rC5a binding to human PMNs. This also resulted in an approx. 600 Da decrease in the molecular mass of rC5a as determined by SDS/PAGE. Incubation of rC5a with the GBS strain GW, which only minimally altered the ability of rC5a to activate human PMNs, did not affect rC5a binding to PMNs and did not alter the molecular mass of rC5a on SDS/PAGE. Plasma-desorption m.s. of rC5a inactivated by GBS 7360 showed that the GBS cleaved the rC5a between histidine-67 and lysine-68 near the C-terminus of rC5a. This mechanism of inactivation of C5a by proteolytic cleavage at the C-terminus of C5a is consistent with the known critical role of the C-terminus in C5a activation of human PMNs. This C5a-cleaving proteinase activity may contribute to the pathophysiology of GBS infections.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1996961      PMCID: PMC1149811          DOI: 10.1042/bj2730635

Source DB:  PubMed          Journal:  Biochem J        ISSN: 0264-6021            Impact factor:   3.857


  21 in total

1.  Effect of intravenous immunoglobulin G on neutrophil kinetics during experimental group B streptococcal infection in neonatal rats.

Authors:  T E Harper; R D Christensen; G Rothstein; H R Hill
Journal:  Rev Infect Dis       Date:  1986 Jul-Aug

Review 2.  Plasma desorption mass spectrometry: coming of age.

Authors:  R J Cotter
Journal:  Anal Chem       Date:  1988-07-01       Impact factor: 6.986

3.  Chemotactic response to human C3a and C5a anaphylatoxins. I. Evaluation of C3a and C5a leukotaxis in vitro and under stimulated in vivo conditions.

Authors:  H N Fernandez; P M Henson; A Otani; T E Hugli
Journal:  J Immunol       Date:  1978-01       Impact factor: 5.422

4.  Mechanism of action of the group A streptococcal C5a inactivator.

Authors:  D E Wexler; D E Chenoweth; P P Cleary
Journal:  Proc Natl Acad Sci U S A       Date:  1985-12       Impact factor: 11.205

5.  Molecular aspects of the serum chemotactic factors.

Authors:  C Gerard; D E Chenoweth; T E Hugli
Journal:  J Reticuloendothel Soc       Date:  1979-12

Review 6.  Structure and function of the anaphylatoxins.

Authors:  T E Hugli
Journal:  Springer Semin Immunopathol       Date:  1984

7.  High-level expression of a gene encoding the human complement factor C5a in Escherichia coli.

Authors:  W Mandecki; B S Powell; K W Mollison; G W Carter; J L Fox
Journal:  Gene       Date:  1986       Impact factor: 3.688

8.  Identification of classical anaphylatoxin as the des-Arg form of the C5a molecule: evidence of a modulator role for the oligosaccharide unit in human des-Arg74-C5a.

Authors:  C Gerard; T E Hugli
Journal:  Proc Natl Acad Sci U S A       Date:  1981-03       Impact factor: 11.205

9.  Assessment of group B streptococcal opsonins in human and rabbit serum by neutrophil chemiluminescence.

Authors:  V G Hemming; R T Hall; P G Rhodes; A O Shigeoka; H R Hill
Journal:  J Clin Invest       Date:  1976-12       Impact factor: 14.808

10.  Chemical synthesis of a gene encoding the human complement fragment C5a and its expression in Escherichia coli.

Authors:  W Mandecki; K W Mollison; T J Bolling; B S Powell; G W Carter; J L Fox
Journal:  Proc Natl Acad Sci U S A       Date:  1985-06       Impact factor: 11.205

View more
  19 in total

1.  Capsular sialic acid limits C5a production on type III group B streptococci.

Authors:  S Takahashi; Y Aoyagi; E E Adderson; Y Okuwaki; J F Bohnsack
Journal:  Infect Immun       Date:  1999-04       Impact factor: 3.441

2.  Identification of novel adhesins from Group B streptococci by use of phage display reveals that C5a peptidase mediates fibronectin binding.

Authors:  Christiane Beckmann; Joshua D Waggoner; Theresa O Harris; Glen S Tamura; Craig E Rubens
Journal:  Infect Immun       Date:  2002-06       Impact factor: 3.441

3.  Structural heterogeneity of the streptococcal C5a peptidase gene in Streptococcus pyogenes.

Authors:  Irina V Koroleva; Androulla Efstratiou; Alexander N Suvorov
Journal:  J Bacteriol       Date:  2002-11       Impact factor: 3.490

4.  Conservation of the C5a peptidase genes in group A and B streptococci.

Authors:  I Chmouryguina; A Suvorov; P Ferrieri; P P Cleary
Journal:  Infect Immun       Date:  1996-07       Impact factor: 3.441

Review 5.  Surface proteins of Streptococcus agalactiae and related proteins in other bacterial pathogens.

Authors:  Gunnar Lindahl; Margaretha Stålhammar-Carlemalm; Thomas Areschoug
Journal:  Clin Microbiol Rev       Date:  2005-01       Impact factor: 26.132

6.  Population structure of Streptococcus agalactiae reveals an association between specific evolutionary lineages and putative virulence factors but not disease.

Authors:  M Hauge; C Jespersgaard; K Poulsen; M Kilian
Journal:  Infect Immun       Date:  1996-03       Impact factor: 3.441

7.  Role of pilus proteins in adherence and invasion of Streptococcus agalactiae to the lung and cervical epithelial cells.

Authors:  Puja Sharma; Hem Lata; Deepak Kumar Arya; Arun Kumar Kashyap; Hemant Kumar; Meenakshi Dua; Arif Ali; Atul Kumar Johri
Journal:  J Biol Chem       Date:  2012-12-03       Impact factor: 5.157

8.  Restricted ability of group B streptococcal C5a-ase to inactivate C5a prepared from different animal species.

Authors:  J F Bohnsack; J K Chang; H R Hill
Journal:  Infect Immun       Date:  1993-04       Impact factor: 3.441

9.  Similarity between the group B and A streptococcal C5a peptidase genes.

Authors:  P P Cleary; J Handley; A N Suvorov; A Podbielski; P Ferrieri
Journal:  Infect Immun       Date:  1992-10       Impact factor: 3.441

10.  Streptococcal C5a peptidase is a highly specific endopeptidase.

Authors:  P P Cleary; U Prahbu; J B Dale; D E Wexler; J Handley
Journal:  Infect Immun       Date:  1992-12       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.